Bimekizumab-bkzx (Bimzelx, UCB) Demonstrates Sustained Skin Clearance in Moderate-to-severe Plaque PsO; A Q & A With Dr. Saakshi Khattri
Saakshi Khattri, MD, a Dermatologist, Rheumatologist, and Internist at the Icahn School of Medicine at Mount Sinai in New York City, chats with TDD about the new results of a five-year study of Bimekizumab-bkzx (Bimzelx, UCB).